BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37134306)

  • 1. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.
    Tamari R; McLornan DP; Ahn KW; Estrada-Merly N; Hernández-Boluda JC; Giralt S; Palmer J; Gale RP; DeFilipp Z; Marks DI; van der Poel M; Verdonck LF; Battiwalla M; Diaz MA; Gupta V; Ali H; Litzow MR; Lazarus HM; Gergis U; Bashey A; Liesveld J; Hashmi S; Pu JJ; Beitinjaneh A; Bredeson C; Rizzieri D; Savani BN; Abid MB; Ganguly S; Agrawal V; Ulrike Bacher V; Wirk B; Jain T; Cutler C; Aljurf M; Kindwall-Keller T; Kharfan-Dabaja MA; Hildebrandt GC; Pawarode A; Solh MM; Yared JA; Grunwald MR; Nathan S; Nishihori T; Seo S; Scott BL; Nakamura R; Oran B; Czerw T; Yakoub-Agha I; Saber W
    Blood Adv; 2023 Aug; 7(15):3993-4002. PubMed ID: 37134306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
    Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.
    Shaffer BC; Ahn KW; Hu ZH; Nishihori T; Malone AK; Valcárcel D; Grunwald MR; Bacher U; Hamilton B; Kharfan-Dabaja MA; Saad A; Cutler C; Warlick E; Reshef R; Wirk BM; Sabloff M; Fasan O; Gerds A; Marks D; Olsson R; Wood WA; Costa LJ; Miller AM; Cortes J; Daly A; Kindwall-Keller TL; Kamble R; Rizzieri DA; Cahn JY; Gale RP; William B; Litzow M; Wiernik PH; Liesveld J; Savani BN; Vij R; Ustun C; Copelan E; Popat U; Kalaycio M; Maziarz R; Alyea E; Sobecks R; Pavletic S; Tallman M; Saber W
    J Clin Oncol; 2016 Jun; 34(16):1864-71. PubMed ID: 27044940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.
    Gupta V; Malone AK; Hari PN; Ahn KW; Hu ZH; Gale RP; Ballen KK; Hamadani M; Olavarria E; Gerds AT; Waller EK; Costa LJ; Antin JH; Kamble RT; van Besien KM; Savani BN; Schouten HC; Szer J; Cahn JY; de Lima MJ; Wirk B; Aljurf MD; Popat U; Bejanyan N; Litzow MR; Norkin M; Lewis ID; Hale GA; Woolfrey AE; Miller AM; Ustun C; Jagasia MH; Lill M; Maziarz RT; Cortes J; Kalaycio ME; Saber W
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):89-97. PubMed ID: 24161923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
    Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
    Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model.
    Hernández-Boluda JC; Pereira A; Alvarez-Larran A; Martín AA; Benzaquen A; Aguirre L; Mora E; González P; Mora J; Dorado N; Sampol A; García-Gutiérrez V; López-Godino O; Fox ML; Reguera JL; Pérez-Encinas M; Pascual MJ; Xicoy B; Parody R; González-Pinedo L; Español I; Avendaño A; Correa JG; Vallejo C; Jurado M; García-Cadenas I; Osorio S; Durán MA; Sánchez-Guijo F; Cervantes F; Piñana JL
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2237-2244. PubMed ID: 32717433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
    Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
    Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
    Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
    Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
    Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
    Raj K; Eikema DJ; McLornan DP; Olavarria E; Blok HJ; Bregante S; Ciceri F; Passweg J; Ljungman P; Schaap N; Carlson K; Zuckerman T; de Wreede LC; Volin L; Koc Y; Diez-Martin JL; Brossart P; Wolf D; Blaise D; Bartolomeo PD; Vitek A; Robin M; Yakoub-Agha I; Chalandon Y; Kroger N
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):522-528. PubMed ID: 30408564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis.
    Keyzner A; Han S; Shapiro S; Moshier E; Schorr E; Petersen B; Najfeld V; Kremyanskaya M; Isola L; Hoffman R; Mascarenhas J
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2180-2186. PubMed ID: 27596130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.
    Bewersdorf JP; Sheth AH; Vetsa S; Grimshaw A; Giri S; Podoltsev NA; Gowda L; Tamari R; Tallman MS; Rampal RK; Zeidan AM; Stahl M
    Transplant Cell Ther; 2021 Oct; 27(10):873.e1-873.e13. PubMed ID: 34052505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.
    Gagelmann N; Ditschkowski M; Bogdanov R; Bredin S; Robin M; Cassinat B; Shahswar R; Thol F; Heuser M; Socié G; Beelen D; Triviai I; Badbaran A; Kröger N
    Blood; 2019 May; 133(20):2233-2242. PubMed ID: 30760453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
    Guru Murthy GS; Kim S; Hu ZH; Estrada-Merly N; Abid MB; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Diaz Perez MA; Farhadfar N; Gale RP; Ganguly S; Gergis U; Hildebrandt GC; Grunwald MR; Hashmi S; Hossain NM; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Hamilton BK; Lazarus HM; Liesveld J; Litzow M; Marks DI; Murthy HS; Nathan S; Nazha A; Nishihori T; Patel SS; Pawarode A; Rizzieri D; Savani B; Seo S; Solh M; Ustun C; van der Poel M; Verdonck LF; Vij R; Wirk B; Oran B; Nakamura R; Scott B; Saber W
    JAMA Oncol; 2022 Mar; 8(3):404-411. PubMed ID: 35024768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
    Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.